Isomorphic Labs’ $2.1B Series B Boosts AI Drug Pipeline Toward 2026 Trials
Alphabet spinout Isomorphic Labs secured $2.1B in Series B funding led by Thrive Capital and backed by Alphabet. The funds will scale its IsoDDE AI drug design engine, expand its 350+ staff across London, Cambridge, Massachusetts and Lausanne, and support advancing candidates to clinical trials by end-2026.
1. Series B Funding Details
Isomorphic Labs closed a $2.1 billion Series B round led by Thrive Capital, with participation from Alphabet, GV, MGX, Abu Dhabi’s sovereign wealth fund, Temasek, CapitalG and the U.K. Sovereign AI Fund. The financing round was completed at an undisclosed valuation, marking the largest private capital raise in AI-driven drug design to date.
2. Funding Allocation and Expansion
The newly raised capital will be used to scale the IsoDDE AI drug design engine, accelerate discovery workflows and broaden the company’s talent pool. Hiring will expand beyond its current 350+ employees across sites in London, Cambridge (Massachusetts) and Lausanne to support larger-scale molecule generation and validation.
3. Pipeline Targets and Timeline
Isomorphic Labs has commenced pre-clinical testing and now targets initiating clinical trials by the end of 2026, shifting from an earlier goal of late 2025. The spinout maintains collaborations with Novartis, Eli Lilly and Johnson & Johnson to co-develop AI-designed drug candidates.